ARCHIVES

Five-Year Course of Tamoxifen Remains Standard Treatment In HR+ Breast Cancer

This article is from The Cancer Letter archive.

Vol. 25 No. 7 | July 26, 2002

Download PDF Visit The Full Archive

Related Articles

Budget Projections for 1978 Offer Clues On Research NCI Hopes To Fund

June 18, 1976

Rauscher “Identifies” Four More Comprehensive Centers

June 21, 1974

ASCO Proposes Principles For Future Debate on Medicaid

November 21, 2014

GAO Report On NCI Cancer Control Contracts (Continued)

August 1, 1980

NCI-Approved CTEP Trials For The Month of July

July 27, 2012

ASPO Honors Gritz.

May 25, 2001